Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: mirati.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $51.00 → $48.00 | Neutral → Buy | Citigroup |
| 8/9/2023 | $45.00 | Neutral → Buy | B. Riley Securities |
| 8/9/2023 | $45.00 | Overweight | Piper Sandler |
| 7/27/2023 | Sector Underperform | Scotiabank | |
| 5/25/2023 | Perform → Outperform | Oppenheimer | |
| 12/14/2022 | Hold | Needham | |
| 12/9/2022 | $121.00 → $53.00 | Buy → Neutral | Citigroup |
| 12/8/2022 | $110.00 → $59.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/8/2022 | $94.00 → $65.00 | Overweight → Neutral | JP Morgan |
| 12/8/2022 | $94.00 → $65.00 | Outperform → Market Perform | BMO Capital Markets |
SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh
Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor listed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancers SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasi
SAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. In the pooled analysis, adagrasib demonstrated durable efficacy with a median overall survival (OS) of 14.1 months and a 2-year OS rate of 31% in patients with previously treated KRASG12C-mutated NSCLC. Exploratory analyses suggested clinical benefit in patients with treated, stable central nervous
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 25,531 shares of Mirati's common stock, and in the aggregate, 15,089 restricted stock units ("RSUs"). The o
SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T. / 3:35 p.m. E.T. Ben Hickey, chief commercial officer, and Jamie Christensen, Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference. Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com. A replay of the webcast will be made available following the event. About Mirati Therapeutics, Inc.® Mirati Therapeutics, Inc. is a commerc
SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity. Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will assume the role of interim CFO. Ms. Stelzer will remain as a consultant to the company through October 2023. "On behalf of the Board and the Company, we thank Laurie for her leadership and the contributions made during her tenure," said Charles M. Baum, M.D., Ph.D., interim CEO, president and founder, Mirati Therapeutics. "It h
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented at the 2023 World Conference on Lung Cancer during the press conference on September 10th 10:35 a.m. – 10:40 a.m. SGT / September 9th 7:35 p.m. – 7:40 p.m. PT and as a mini-oral presentation in the "Targeted Therapy: KRAS and Beyond" session occurring on September 10th at 4:22 p.m. SGT / 1:22 a
SAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the closing of its previously announced underwritten public offering of 11,288,336 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares